)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Coya Therapeutics
Coya Therapeutics (COYA) investor relations material
Coya Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary10 Nov, 2026
Executive summary
COYA 302 Phase 2/3 ALSTARS enrollment completed at 137 participants versus 120 planned; FDA granted Fast Track Designation for ALS in May 2026.
ALSTARS topline data from the 24-week double-blind phase is expected in early Q2 2027; an open-label extension will offer continued COYA 302 treatment.
No product sales have been recorded; revenue comes from the Dr. Reddy’s collaboration, while development and operating costs drive losses.
Financial highlights
Q3 2026 collaboration revenue was $234,134 vs. $3.56M YoY; Q3 2025 included $3.3M of immediately recognized license revenue.
Q3 net loss was $10.62M vs. $2.12M, with loss per share of $0.45 vs. $0.13; operating loss was $10.9M vs. $2.4M.
Q3 R&D expense rose to $8.57M from $2.92M, primarily reflecting COYA 302 ALS trial costs; G&A was $2.6M in both periods.
9M 2026 collaboration revenue was $729,026 vs. $3.99M; net loss was $24.46M vs. $15.52M and loss per share was $1.05 vs. $0.93.
9M R&D expense increased to $17.70M from $11.79M; other income was $1.17M vs. $1.01M, primarily reflecting higher interest earned on cash balances.
Outlook and guidance
Cash of $35.80M at September 30, 2026, was expected to fund planned operations into H2 2027 and past the ALSTARS topline readout; management also concluded funds would not support operations for more than one year after issuance of the statements.
Significant additional financing is expected to support trials and operations; spending is expected to rise with later-stage development and manufacturing scale-up.
Additional ALS and AD mechanistic and single-cell proteomics data were expected in 4Q 2026–Q1 2027, subject to publication; FTD biomarker data was expected in Q1 2027.
A Phase 2 COYA 302 study in FTD is planned for 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Coya Therapeutics
- COYA 302 ALS topline is expected early Q2 2027, with cash runway into H2 2027.COYA
Investor presentation - ALSTARS is fully enrolled, with ALS topline data expected early Q2 2027.COYAInvestor presentation
- Treg-based combination therapies show promise in ALS and FTD, with key data expected in 2027.COYAInvestor presentation
- Treg-based therapies show promise in ALS and FTD, with key Phase 2 data expected in 2027.COYAInvestor presentation
- Q2 2026 net loss rose to $6.6M as R&D spending increased and $43.2M cash remained.COYAQ2 2026
- COYA 302 advances to phase 2B ALS trial, with major data and partnership milestones set for 2025.COYAOppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025
- Treg-targeted therapies advance in ALS and FTD, with pivotal data expected in 2027.COYAInvestor presentation
- Board elections, auditor ratification, and clinical milestones highlighted; all proposals approved.COYAAGM 2026
- Inflammation-driven brain injury from repetitive trauma is a major public health concern.COYAInvestor update
Next Coya Therapeutics earnings date
Q4 202616 Mar, 2027
Coya Therapeutics
Next Coya Therapeutics earnings date
Q4 202616 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing proprietary therapies that enhance the function of regulatory T cells (Tregs). The company’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. These therapies are aimed at treating neurodegenerative, autoimmune, and metabolic diseases. Coya Therapeutics is headquartered in Houston, Texas, and its shares are listed on the NASDAQ.